Newsroom

06

September 2019

Friday

iX Biopharma Ltd participated in SGX’s 20th anniversary celebrations by striking the SGX gong to open the Singapore securities market on 6 September 2019. The Company commemorated its milestones since listing and shared about its growth drivers and market trends impacting the healthcare industry.

Read On

23

August 2019

Friday

iX Biopharma Ltd. has reported results for the fourth financial quarter and financial year ended 30 june 2019

The fourth quarter financial statements for the period can be found here.

21

May 2019

Tuesday

iX Biopharma is pleased to announce that following the completion of its Phase 2 clinical study on Wafermine, a sublingual racemic ketamine wafer for the treatment of acute moderate to severe pain, the U.S. Food and Drug Administration (FDA) has scheduled the End-of-Phase 2 (EOP2) meeting with the Company in the third quarter of 2019. Wafermine is the first sublingual ketamine drug seeking FDA approval for the treatment of moderate to severe acute pain, and is a Phase 2-ready drug for treatment resistant depression.

More information can be found in the attached press release.

09

May 2019

Thursday

iX Biopharma Ltd. has reported results for the third financial quarter and nine months ended 31st March 2019.

The third quarter financial statements for the period can be found here.

18

March 2019

Monday

The Board of Directors of iX Biopharma Ltd. is pleased to announce that the Company has successfully completed the sale of Chemical Analysis Pty Ltd to Eurofins Australia New Zealand Holding Pty Ltd. 

More information can be found in the attached press release

18

February 2019

Monday

The Board of Directors of iX Biopharma Ltd. wishes to announce that the Company has entered into a sale and purchase agreement with Eurofins Australia New Zealand Holding Pty Ltd (the “Purchaser”), an independent third party, on 15 February 2019 in respect of the proposed disposal of the Company’s entire shareholding interest (comprising 20 ordinary shares) in the Company’s wholly-owned subsidiary, Chemical Analysis Pty Ltd to the Purchaser. 

More information on the proposed disposal of the laboratory testing business can be found here

11

February 2019

Monday

iX Biopharma Ltd. has reported results for the second financial quarter and first half-year ended 31 December 2018 (unaudited).

The second quarter financial statements for the period can be found here.

12

November 2018

Monday

iX Biopharma Ltd. has reported results for the first quarter ended 30 September 2018 (unaudited). 

The first quarter financial statements for the period can be found here.

05

November 2018

Monday

iX Biopharma Ltd will be presenting the positive results from the Phase 2 clinical KET010 study for Wafermine, its lead product under development for the treatment of moderate to severe acute pain at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark. Dr Janakan Krishnarajah, iX Biopharma’s Chief Medical Officer, will be presenting the results on 6 November 2018 at 3:00pm (GMT+1).  

More information can be found in the attached press release. The presentation slides can be accessed here.

27

September 2018

Thursday

iX Biopharma Ltd has published its Annual Report for FY2018.

The Annual Report can be found here, together with the Notice of AGM

For all company announcements, please refer to SGX company disclosures page.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com